Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Aplastic anemia (2)
- CAR-T cells (2)
- Chronic myeloid leukemia (2)
- Eltrombopag (2)
- Glioblastoma (2)
-
- Prognosis (2)
- Thrombocytopenia (2)
- 21-gene genomic assay (1)
- APL (1)
- Acute myeloid leukemia (1)
- Adoptive therapy (1)
- Age (1)
- Allogeneic (1)
- Allogeneic hematopoietic cell transplantation (1)
- Allogeneic stem cell transplant (1)
- Angiogenesis (1)
- Apoptosis (1)
- Armenia (1)
- Arrhythmia (1)
- Autologous (1)
- B-cell malignancies (1)
- BCR-ABL1 transcript (1)
- Beta-thalassemia (1)
- Breast cancer (1)
- CALR (1)
- CAR-NK cells (1)
- CDK4/6 inhibitors (1)
- CMT (1)
- COVID-19 (1)
- CTLA-4 inhibitors (1)
Articles 1 - 30 of 62
Full-Text Articles in Medicine and Health Sciences
Emerging Role Of Autologous Cd19 Car T-Cell Therapies In The Second-Line Setting For Large B-Cell Lymphoma: A Game Changer?, Razan Mohty, Muhamad A. Moustafa, Mahmoud Aljurf, Hemant Murthy, Mohamed A. Kharfan-Dabaja
Emerging Role Of Autologous Cd19 Car T-Cell Therapies In The Second-Line Setting For Large B-Cell Lymphoma: A Game Changer?, Razan Mohty, Muhamad A. Moustafa, Mahmoud Aljurf, Hemant Murthy, Mohamed A. Kharfan-Dabaja
Hematology/Oncology and Stem Cell Therapy
Chimeric antigen receptor T-cell (CAR T) therapy has been proven effective in the third-line (and beyond) setting in patients with large B-cell lymphoma (LBCL). Until recently, high-dose chemotherapy followed by autologous hematopoietic cell transplantation (auto-HCT) was considered the standard of care in the second-line setting in patients demonstrating an objective response before the procedure. The ZUMA-7 and TRANSFORM studies showed the benefit of axicabtagene ciloleucel and lisocabtagene maraleucel, respectively, in patients refractory to or relapsing within 12 months of first-line anthracycline-based chemoimmunotherapy. However, a third trial using tisagenlecleucel failed to show a benefit in the same setting compared to standard …
The Phenomenon Of Multidrug Resistance In Glioblastomas, Alexandr N. Chernov, Diana A. Alaverdian, Elvira S. Galimova, Alessandra Renieri, Elisa Frullanti, Ilaria Meloni, Olga V. Shamova
The Phenomenon Of Multidrug Resistance In Glioblastomas, Alexandr N. Chernov, Diana A. Alaverdian, Elvira S. Galimova, Alessandra Renieri, Elisa Frullanti, Ilaria Meloni, Olga V. Shamova
Hematology/Oncology and Stem Cell Therapy
The most common and aggressive brain tumor in the adult population is glioblastoma (GBM). The lifespan of patients does not exceed 22 months. One of the reasons for the low effectiveness of GBM treatment is its radioresistance and chemoresistance. In the current review, we discuss the phenomenon of multidrug resistance of GBM in the context of the expression of ABC family transporter proteins and the mechanisms of proliferation, angiogenesis, and recurrence. We focused on the search of molecular targets among growth factors, receptors, signal transduction proteins, microRNAs, transcription factors, proto-oncogenes, tumor suppressor genes, and their single-nucleotide polymorphisms.
The Hispanic Paradox In Non-Small Cell Lung Cancer, Rohit Kumar, Franklin Castillero, Shruti Bhandari, Sindhu Malapati, Goetz Kloecker
The Hispanic Paradox In Non-Small Cell Lung Cancer, Rohit Kumar, Franklin Castillero, Shruti Bhandari, Sindhu Malapati, Goetz Kloecker
Hematology/Oncology and Stem Cell Therapy
Objective/Background: According to the U.S. Census Bureau, 18% of the total population in the United States identified themselves as Hispanic in 2016 making it the largest minority group. This study aimed to evaluate the effect of Hispanic ethnicity on the overall survival of patients with non-small cell lung cancer (NSCLC) using a large national cancer database. Methods: We used the National Cancer Database to identify patients diagnosed with NSCLC between 2010 and 2015. The two comparative groups for this study were non-Hispanic Whites (NHWs) and Hispanics. The primary outcome was overall survival. Results: Of the 555,475 patients included in the …
Impact Of The Major Bcr-Abl1 Transcript Type On Clinical And Biological Parameters And Molecular Response In Patients With Chronic Myeloid Leukemia, Mourad Nachi, Ibtissem Kihel, Badra Entasoltane, Mohamed Brahimi, Nabil Yafour, Djaoued Guella, Amine Abed, Mohamed A. Bekadja
Impact Of The Major Bcr-Abl1 Transcript Type On Clinical And Biological Parameters And Molecular Response In Patients With Chronic Myeloid Leukemia, Mourad Nachi, Ibtissem Kihel, Badra Entasoltane, Mohamed Brahimi, Nabil Yafour, Djaoued Guella, Amine Abed, Mohamed A. Bekadja
Hematology/Oncology and Stem Cell Therapy
Aim: In chronic myeloid leukemia (CML), the impact of MBCR-ABL1 major transcript type on disease phenotype and response to treatment still controversial to date. This work aims to study the influence of Mb3a2 and Mb2a2 transcripts on clinico-biological parameters and the molecular response in patients with chronic phase chronic myeloid leukemia (CP-CML) treated with Imatinib as frontline therapy. Methods: This is six years prospective study started in March 1 st, 2013. 67 patients with newly CP-CML were treated by Imatinib as frontline therapy. Clinical and biological characteristics disease were collected for all patients. Molecular typing was performed by multiplex RT-PCR …
Hepatitis-Associated Aplastic Anemia, Alfadel Alshaibani, Carlo Dufour, Antonio Risitano, Regis De Latour, Mahmoud Aljurf
Hepatitis-Associated Aplastic Anemia, Alfadel Alshaibani, Carlo Dufour, Antonio Risitano, Regis De Latour, Mahmoud Aljurf
Hematology/Oncology and Stem Cell Therapy
Hepatitis-associated aplastic anemia (HAAA) is a rare illness, characterized by onset of pancytopenia with a hypoplastic bone marrow that traditionally occurs within 6 months of an increase in serum aminotransferases. HAAA is observed in 1% to 5% of all newly diagnosed cases of acquired aplastic anemia. Several hepatitis viruses have been linked to the disease, but in many cases no specific virus is detected. The exact pathophysiology is unknown; however, immune destruction of hematopoietic stem cells is believed to be the underlying mechanism. HAAA is a potentially lethal disease if left untreated. Management includes immunosuppression with antithymocyte globulin and cyclosporine …
Does Race Play A Role In Complications And Outcomes Of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms?, Andrew M. Peseski, Antoine N. Saliba, Sandra K. Althouse, Hamid Sayar
Does Race Play A Role In Complications And Outcomes Of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms?, Andrew M. Peseski, Antoine N. Saliba, Sandra K. Althouse, Hamid Sayar
Hematology/Oncology and Stem Cell Therapy
Background: Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are a group of hematologic malignancies with known vascular complications. The role race and ethnicity play in these complications is less defined. We aimed to further evaluate the role of race in patients without a history of previous thrombotic or hemorrhagic events. Methods: In this retrospective study, 300 adult patients with MPN were included; 270 (90.0%) were White and 30 (10.0%) were non-White. The non-White group primarily consisted of African American or Black (26 patients), followed by others. Median age at diagnosis was 58 years for White patients and 61.5 years for non-White patients. …
Spectrum Of Myelodysplastic Syndrome In Patients Evaluated For Cytopenia(S). A Report From A Reference Centre In Saudi Arabia, Nour Almozain, Ayman Mashi, Qasem Alneami, Amal Al-Omran, Nasir Bakshi, Tarek Owaidah, Salem Khalil, Haitham Khogeer, Shahrukh Hashmi, Suleimman Al-Sweedan, Thomas Morris, Randa Alnounou
Spectrum Of Myelodysplastic Syndrome In Patients Evaluated For Cytopenia(S). A Report From A Reference Centre In Saudi Arabia, Nour Almozain, Ayman Mashi, Qasem Alneami, Amal Al-Omran, Nasir Bakshi, Tarek Owaidah, Salem Khalil, Haitham Khogeer, Shahrukh Hashmi, Suleimman Al-Sweedan, Thomas Morris, Randa Alnounou
Hematology/Oncology and Stem Cell Therapy
Background/Objective: Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells, characterized by ineffective hematopoiesis, peripheral cytopenias along with hypercellularity of the bone marrow, and marked dysplastic features. Establishing MDS diagnosis is difficult due to nonspecific clinical presentation and imprecise morphological criteria. In anticipation to improve the diagnostic approach in this field, we aimed to characterize the clinical and morphological features of patients presented with cytopenias with a special focus on MDS. Methods: We comprehensively reviewed all medical record of patients who were referred to the hematology laboratory at KFSH-RC, Riyadh, Saudi Arabia, between January 2009 and March 2016 …
The Risk And Prognosis Of Covid-19 Infection In Cancer Patients: A Systematic Review And Meta-Analysis, Ghada M. Elgohary, Shahrukh Hashmi, Jan Styczynski, Mohamed A. Kharfan-Dabaja, Rehab M. Alblooshi, Rafael De La Camara, Sherif Mohmed, Alfadel Alshaibani, Simone Cesaro, Nashwa Abd El-Aziz, Reem Almaghrabi, Usama Gergis, Navneet S. Majhail, Roy F. Chemaly, Mahmoud Aljurf, Riad El Fakih
The Risk And Prognosis Of Covid-19 Infection In Cancer Patients: A Systematic Review And Meta-Analysis, Ghada M. Elgohary, Shahrukh Hashmi, Jan Styczynski, Mohamed A. Kharfan-Dabaja, Rehab M. Alblooshi, Rafael De La Camara, Sherif Mohmed, Alfadel Alshaibani, Simone Cesaro, Nashwa Abd El-Aziz, Reem Almaghrabi, Usama Gergis, Navneet S. Majhail, Roy F. Chemaly, Mahmoud Aljurf, Riad El Fakih
Hematology/Oncology and Stem Cell Therapy
Numerous studies have been published regarding outcomes of cancer patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus causing the coronavirus disease 2019 (COVID-19) infection. However, most of these are single-center studies with a limited number of patients. To better assess the outcomes of this new infection in this subgroup of susceptible patients, we performed a systematic review and meta-analysis to evaluate the impact of COVID-19 infection on cancer patients. We performed a literature search using PubMed, Web of Science, and Scopus for studies that reported the risk of infection and complications of COVID-19 in cancer patients …
Clinicopathological Significance Of Common Genetic Alterations In Patients With Acute Promyelocytic Leukemia, Sukanta Nath, Jina Bhattacharyya, Prem Chandra, Renu Saxena, Sudha Sazawal, Kandarpa Kumar Saikia
Clinicopathological Significance Of Common Genetic Alterations In Patients With Acute Promyelocytic Leukemia, Sukanta Nath, Jina Bhattacharyya, Prem Chandra, Renu Saxena, Sudha Sazawal, Kandarpa Kumar Saikia
Hematology/Oncology and Stem Cell Therapy
Objective/Background: Acute myeloid leukemia (AML) is one of the common forms of hematological malignancy and acute promyelocytic leukemia (APL) is a unique subtype of AML conferring favorable prognosis. We aimed to determine the prevalence and prognostic impact of Fms-like tyrosine kinase 3 (FLT3), nucleophosmin 1 (NPM1) mutation, epidermal growth factor receptor (EGFR), and flow marker’s expression in patients with APL. Methods: In the present study, 165 de novo APL patients were molecularly characterized for promyelocytic leukemia (PML) breakpoint and additional genetic alterations. Reverse transcriptase polymerase chain reaction (PCR) and real time PCR assays were used to detect genetic alterations. Results: …
Familial Emberger Syndrome With Autoimmunity, Hyper-Immunoglobulin E And Lymphatic Impairment Caused By A Novel Gata2 Mutation, Moneerah Algassim, Ahad F. Al Seraihi, Alfadel Alshaibani, Walter Conca, Saleem Alshehri, Moheieldin Moustafa Abouzied, Issam Hamadah, Saleh Alreshoodi, Majed Dasouki, Farrukh Sheikh
Familial Emberger Syndrome With Autoimmunity, Hyper-Immunoglobulin E And Lymphatic Impairment Caused By A Novel Gata2 Mutation, Moneerah Algassim, Ahad F. Al Seraihi, Alfadel Alshaibani, Walter Conca, Saleem Alshehri, Moheieldin Moustafa Abouzied, Issam Hamadah, Saleh Alreshoodi, Majed Dasouki, Farrukh Sheikh
Hematology/Oncology and Stem Cell Therapy
No abstract provided.
Mutation Profile In Bcr-Abl1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India, Madhavi Maddali, Uday Prakash Kulkarni, Niveditha Ravindra, Arun Kumar Arunachalam, Arvind Venkatraman, Sharon Lionel, Marie Therese Manipadam, Anup J. Devasia, Anu Korula, N.A. Fouzia, Aby Abraham, Alok Srivastava, Biju George, Poonkuzhali Balasubramanian, Vikram Mathews
Mutation Profile In Bcr-Abl1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India, Madhavi Maddali, Uday Prakash Kulkarni, Niveditha Ravindra, Arun Kumar Arunachalam, Arvind Venkatraman, Sharon Lionel, Marie Therese Manipadam, Anup J. Devasia, Anu Korula, N.A. Fouzia, Aby Abraham, Alok Srivastava, Biju George, Poonkuzhali Balasubramanian, Vikram Mathews
Hematology/Oncology and Stem Cell Therapy
Objective/Background: Recurrent somatic mutations in the JAK2, calreticulin (CALR), and the MPL genes are described as drivers of BCR-ABL1-negative myeloproliferative neoplasms (MPN) that includes polycythemia vera (PV), essential thrombocytosis (ET), primary myelofibrosis (PMF), and MPN unclassified (MPN-U). Methods: We describe the mutation profile and clinical features of MPN cases diagnosed at a tertiary care center. JAK2V617F and MPL (S505/W515) mutations were screened by allele-specific polymerase chain reaction, while CALR exon 9 and JAK2 exon 12 mutations were screened by fragment analysis/Sanger sequencing. Among the 1,570 patients tested for these mutations during the study period, 407 were classified as MPN with …
Philadelphia Chromosome-Positive T-Cell Acute Lymphoblastic Leukemia: A Case Report And Review Of The Literature, Ahmad Alshomar, Riad El Fakih
Philadelphia Chromosome-Positive T-Cell Acute Lymphoblastic Leukemia: A Case Report And Review Of The Literature, Ahmad Alshomar, Riad El Fakih
Hematology/Oncology and Stem Cell Therapy
No abstract provided.
Fatal Autoimmune Storm After A Single Cycle Of Anti-Pd-1 Therapy: A Case Of Lethal Toxicity But Pathological Complete Response In Metastatic Lung Adenocarcinoma, Jesús Fuentes-Antras, Paloma Peinado, Kissy Guevara-Hoyer, Cristina Díaz Del Arco, Silvia Sanchez-Ramon, Carlos Aguado
Fatal Autoimmune Storm After A Single Cycle Of Anti-Pd-1 Therapy: A Case Of Lethal Toxicity But Pathological Complete Response In Metastatic Lung Adenocarcinoma, Jesús Fuentes-Antras, Paloma Peinado, Kissy Guevara-Hoyer, Cristina Díaz Del Arco, Silvia Sanchez-Ramon, Carlos Aguado
Hematology/Oncology and Stem Cell Therapy
As immunotherapy agents are incorporated into the routine oncological practice, the number of patients at the risk of immune-related adverse events has increased dramatically. However, the prompt identification and effective management of severe autoimmune complications remain a challenge. We report the case of a patient with metastatic lung adenocarcinoma who experienced a fatal autoimmune storm 3 weeks after the first dose of anti-programmed death receptor-1 (PD-1) agent pembrolizumab, which included thyroiditis, hepatitis, myositis, myocarditis, pneumonitis, and myasthenia gravis. Aggressive autoimmunity was supported by extensive T-cell and macrophage tissue infiltrates and autoantibody positivity. Remarkably, no residual tumor was found at autopsy. …
Ofatumumab For Post-Transplant Lymphoproliferative Disorder, Madhav Seshadri, Genevieve M. Crane, Usama Gergis
Ofatumumab For Post-Transplant Lymphoproliferative Disorder, Madhav Seshadri, Genevieve M. Crane, Usama Gergis
Hematology/Oncology and Stem Cell Therapy
Posttransplant lymphoproliferative disorder (PTLD) includes a range of abnormal lymphoid proliferation following solid organ or allogeneic hematopoietic stem cell transplantation (HSCT), often associated with EpsteineBarr virus (EBV) infection. Treatment generally incudes rituximab, a chimeric monoclonal antibody directed against CD20. Here we present a 56-year-old woman with EBV-associated PTLD following allogeneic HSCT who was intolerant of rituximab. The patient was instead treated with ofatumumab, a fully human monoclonal antibody directed against CD20, with significant response in EBV viral load and lymphadenopathy. Ofatumumab could represent an important treatment option for patients unable to tolerate rituximab.
Evaluation Of Eltrombopag In Thrombocytopenia Post Hematopoietic Cell Transplantation, H Samarkandi, M Al Nahedh, A Alfattani, F Alsharif, N Bakshi, W Rasheed, F Alfraih, M Alhumaid, Nora Alkhudair, S Alhayli, H Alsaedi, M Shaheen, A Hanbali, S.K. Hashmi, E Devol, A Alseraihy, H Alzahrani, M Aljurf
Evaluation Of Eltrombopag In Thrombocytopenia Post Hematopoietic Cell Transplantation, H Samarkandi, M Al Nahedh, A Alfattani, F Alsharif, N Bakshi, W Rasheed, F Alfraih, M Alhumaid, Nora Alkhudair, S Alhayli, H Alsaedi, M Shaheen, A Hanbali, S.K. Hashmi, E Devol, A Alseraihy, H Alzahrani, M Aljurf
Hematology/Oncology and Stem Cell Therapy
Background: Thrombocytopenia remains a life-threatening late complication of HCT with an incidence of 5e20%. Currently, there is no approved drug for the treatment of persistent thrombocytopenia post HCT and platelet transfusion is the maintain stay of treatment. Eltrombopag is approved for the treatment of thrombocytopenia associated with different diseases, however; data on eltrombopag treatment post HCT are limited. Methods: This is a retrospective cohort study evaluating the effect of eltrombopag on platelet recovery in patients with persistent thrombocytopenia post HCT. The primary endpoint was platelet recovery to ≥ 20,000/mL for 7 consecutive days without transfusion support after starting eltrombopag. Secondary …
Prevalence And Distribution Of Major -Thalassemia Mutations And Hbe/-Thalassemia Variant In Nepalese Ethnic Groups, Zilfalil Bin Alwi, Raju Lama, Wardah Yusof, Tilak R. Shrestha, Sarifah Hanafi, Matrika Bhattarai, Rosline Hassan, Bin Alwi Zilfalil
Prevalence And Distribution Of Major -Thalassemia Mutations And Hbe/-Thalassemia Variant In Nepalese Ethnic Groups, Zilfalil Bin Alwi, Raju Lama, Wardah Yusof, Tilak R. Shrestha, Sarifah Hanafi, Matrika Bhattarai, Rosline Hassan, Bin Alwi Zilfalil
Hematology/Oncology and Stem Cell Therapy
Background: Beta-thalassemia is a genetic disorder that is inherited in an autosomal recessive pattern. This genetic disease leads to a defective beta-globin hemoglobin chain causing partial or complete beta-globin chain synthesis loss. Beta-thalassemia major patients need a continuous blood transfusion and iron chelation to maintain the normal homeostasis of red blood cells (RBCs) and other systems in the body. Patients also require treatment procedures that are costly and tedious, resulting in a serious health burden for developing nations such as Nepal. Methods: A total of 61 individuals clinically diagnosed to have thalassemia were genotyped with multiplex amplification refractory mutation systemepolymerase …
Outcome Of Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation As A Treatment Option In Patients With Severe Aplastic Anemia Between 40 And 50 Years, Hosein Kamranzadeh Fumani, Mahdi Jalili, Soroush Rad, Davood Babakhani, Nasrollah Maleki, Seyed Asadollah Mousavi, Ardeshir Ghavamzadeh
Outcome Of Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation As A Treatment Option In Patients With Severe Aplastic Anemia Between 40 And 50 Years, Hosein Kamranzadeh Fumani, Mahdi Jalili, Soroush Rad, Davood Babakhani, Nasrollah Maleki, Seyed Asadollah Mousavi, Ardeshir Ghavamzadeh
Hematology/Oncology and Stem Cell Therapy
The frontline treatment for patients younger than 40 years with severe aplastic anemia (AA) is allogeneic hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen-identical sibling donor. However, in patients with severe AA who are older than 40 years, allogeneic HSCT has been found to be associated with increased treatment related mortality and toxicity, even when matched sibling donors are used. We report our institutional experience with allogeneic HSCT in patients with severe AA between 40 and 50 years. A total of 19 patients with severe AA were included in the study. Overall survival (OS) and disease-free survival (DFS) …
Using The Appropriate Formula For Qt Measurement Can Save Lives, Taher Taher Al-Tweigeri Taher
Using The Appropriate Formula For Qt Measurement Can Save Lives, Taher Taher Al-Tweigeri Taher
Hematology/Oncology and Stem Cell Therapy
CDK 4/6 inhibitors, in combination with endocrine therapy, are the standard of care for patients with endocrine sensitive advanced breast cancer. This class of drug, however, is associated with QT prolongation, which serves as a surrogate marker for Torsades de Pointes (TdP), a cause of life-threatening ventricular arrhythmias and sudden cardiac death. The ICH E14 guidance document uses the Bazett formula for reporting of cardio-dynamic and safety ECG data in clinical trials. While there is substantial familiarity with the Bazett (QTcB) formula (QT/(RR) 1/2), the Fridericia (QTcF) formula (QT/(RR) 1/3 ) is preferred in the cancer population as it is …
Update On The Availability Of Essential Medications For Pediatric Cancer Patients In Armenia: How To Solve The Problem?, Saten Hovhannisyan, Julieta Hoveyan, Tigran Aghabekyan, Gevorg Tamamyan
Update On The Availability Of Essential Medications For Pediatric Cancer Patients In Armenia: How To Solve The Problem?, Saten Hovhannisyan, Julieta Hoveyan, Tigran Aghabekyan, Gevorg Tamamyan
Hematology/Oncology and Stem Cell Therapy
No abstract provided.
Stem Cell-Based Therapies And Glioblastoma: A Seminal Matter, Kumaria Ashwin, Ashwin Kumaria
Stem Cell-Based Therapies And Glioblastoma: A Seminal Matter, Kumaria Ashwin, Ashwin Kumaria
Hematology/Oncology and Stem Cell Therapy
No abstract provided.
A Novel Frameshift Mutation In The Itgb3 Gene Leading To Glanzmann’S Thrombasthenia In A Saudi Arabian Family, Asma Alharbi, Jamil A. Hashmi, Essa Alharby, Alia M. Albalawi, Khushnooda Ramzan, Sulman Basit
A Novel Frameshift Mutation In The Itgb3 Gene Leading To Glanzmann’S Thrombasthenia In A Saudi Arabian Family, Asma Alharbi, Jamil A. Hashmi, Essa Alharby, Alia M. Albalawi, Khushnooda Ramzan, Sulman Basit
Hematology/Oncology and Stem Cell Therapy
Glanzmann’s thrombasthenia (GT) is an autosomal recessive congenital bleeding disorder of platelet aggregation. Mutations in ITGA2B and ITGB3 genes result in quantitative and/or qualitative abnormalities of the glycoprotein receptor complex IIb/IIIa (integrin aIIbb3), which in turn impairs platelet aggregation and lead to GT. In this study, whole genome single nucleotide polymorphism (SNP) genotyping as well as whole exome sequencing was performed in a large family segregating GT. Analysis of the genotypes localized the disease region to chromosome 17q21.2eq21.3. Filtration of whole exome data and candidate variants prioritization identified a pathogenic variant in the ITGB3 gene. The single nucleotide deletion variant …
Predictors Of Outcomes Of Therapy-Related Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation, Ram Vasudevan Nampoothiri, Arjun Datt Law, Wilson Lam, Carol Chen, Zeyad Al-Shaibani, David Loach, Fotios V. Michelis, Dennis Dong Hwan Kim, Jonas Mattsson, Rajat Kumar, Jeffrey Howard Lipton, Auro Viswabandya
Predictors Of Outcomes Of Therapy-Related Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation, Ram Vasudevan Nampoothiri, Arjun Datt Law, Wilson Lam, Carol Chen, Zeyad Al-Shaibani, David Loach, Fotios V. Michelis, Dennis Dong Hwan Kim, Jonas Mattsson, Rajat Kumar, Jeffrey Howard Lipton, Auro Viswabandya
Hematology/Oncology and Stem Cell Therapy
Background/Objective: Existing literature on allogeneic hematopoietic stem cell transplantation (allo-HSCT) in therapy related acute myeloid leukemia (t-AML) is confounded by the inclusion of patients with secondary AML and t-MDS. We aim to report our 20-year experience of HSCT in t-AML. Methods: We retrospectively reviewed patients with t-AML who underwent HSCT. Patients were analyzed for prior malignancy, therapy, time to diagnosis of t-AML, transplant details, relapse-free survival (RFS), overall survival (OS), and predictors of outcomes. Results: In total, 68 patients (59.9% female; median age, 56.5 years) underwent HSCT. Acute and chronic graft-versus host disease (GVHD) occurred in 39 (57.4%) and 23 …
Efficacy Of Allogeneic Hematopoietic Cell Transplantation In Patients With Chronic Phase Cml Resistant Or Intolerant To Tyrosine Kinase Inhibitors, Farah Yassine, Tea Reljic, Muhamad Alhaj Moustafa, Madiha Iqbal, Hemant S. Murthy, Ambuj Kumar, Mohamed A. Kharfan-Dabaja
Efficacy Of Allogeneic Hematopoietic Cell Transplantation In Patients With Chronic Phase Cml Resistant Or Intolerant To Tyrosine Kinase Inhibitors, Farah Yassine, Tea Reljic, Muhamad Alhaj Moustafa, Madiha Iqbal, Hemant S. Murthy, Ambuj Kumar, Mohamed A. Kharfan-Dabaja
Hematology/Oncology and Stem Cell Therapy
Approximately 15-20% of chronic myeloid leukemia (CML) patients fail tyrosine kinase inhibitor (TKI) therapy secondary to resistance or intolerance. In the pre-TKI era, front-line allogeneic hematopoietic cell transplantation (alloHCT) represented the standard approach for patients with chronic phase-CML (CP-CML) who were deemed fit to tolerate the procedure and had a human leukocyte antigen compatible donor available. Currently, CP-CML patients are eligible for allo-HCT only if they fail more than one TKI and/or are intolerant to the drug. We performed a systematic review/meta-analysis of the available literature to assess the evidence regarding allo-HCT efficacy in CP-CML patients. Data from eligible studies …
Recurrence Score Testing Does Not Appear To Benefit Patients With Grade 1, Progesterone Receptor Positive Breast Cancers: An Opportunity To Eliminate Over-Treatment And Decrease Testing Costs, Udai S. Sibia, Thomas J. Sanders, Charles Mylander, Martin Rosman, Carol Tweed, Lorraine Tafra, Rubie S. Jackson
Recurrence Score Testing Does Not Appear To Benefit Patients With Grade 1, Progesterone Receptor Positive Breast Cancers: An Opportunity To Eliminate Over-Treatment And Decrease Testing Costs, Udai S. Sibia, Thomas J. Sanders, Charles Mylander, Martin Rosman, Carol Tweed, Lorraine Tafra, Rubie S. Jackson
Hematology/Oncology and Stem Cell Therapy
Background: We previously described a risk prediction model (Anne Arundel Medical Center [AAMC] model) based on pathology which may eliminate the need for recurrence score (RS) testing in select early-stage breast cancers. There is a concern that patients in discordant risk prediction groups (AAMC vs. RS) may be overtreated or undertreated if RS testing were omitted. Methods: We queried the Surveillance, Epidemiology, and End Results (SEER) database for all breast cancer patients between 2004 and 2015. AAMC low-risk was defined as Grade 1 and progesterone receptor-positive (PR þ ) tumors, while AAMC high-risk was defined as Grade 3 or estrogen-negative …
Use Of Thrombopoietin Receptor Agonists In Pregnancy: A Review Of The Literature, Jude Howaidi, Abdullah M. Alrajhi, Ali Howaidi, Fouad H. Alnajjar, Imran K. Tailor
Use Of Thrombopoietin Receptor Agonists In Pregnancy: A Review Of The Literature, Jude Howaidi, Abdullah M. Alrajhi, Ali Howaidi, Fouad H. Alnajjar, Imran K. Tailor
Hematology/Oncology and Stem Cell Therapy
The management of immune thrombocytopenic purpura (ITP) involves several lines of therapy such as corticosteroids and intravenous immunoglobulin. With the emergence of novel therapies such as thrombopoietin receptor agonists (TPO-RAs), there has been a shift in treatment modalities. Eltrombopag and romiplostim have proven to be effective in the management of ITP through clinical studies, but their safety in pregnancy remains uncertain. The purpose of the study is to review the literature to evaluate the safety of TPO-RAs in pregnant women. Ten case reports and a cohort study pertaining to the use of TPO-RAs in pregnancy were obtained. According to the …
Allogeneic Chimeric Antigen Receptor T Cells For Hematologic Malignancies, Yang Yang, Xia Bi, Mia Gergis, Dongni Yi, Jingmei Hsu, Usama Gergis
Allogeneic Chimeric Antigen Receptor T Cells For Hematologic Malignancies, Yang Yang, Xia Bi, Mia Gergis, Dongni Yi, Jingmei Hsu, Usama Gergis
Hematology/Oncology and Stem Cell Therapy
Autologous chimeric antigen receptor (CAR)Tcell therapy has been extensively studied over the past decades. Currently, autologous CAR T products are FDA-approved to treat B cell acute lymphoblastic leukemia (B-ALL), large B cell, mantle cell, and follicular lymphomas, and multiple myeloma. However, this therapy has drawbacks including higher cost, production lead time, logistical complexity, and higher risk of manufacturing failure. Alternatively, allogeneic CAR T cell therapy, currently under clinical trial, has inherent disadvantages, including cell rejection, graft versus host disease, and undetermined safety and efficacy profiles. Different strategies, including modifying HLA and T cell receptor expression using different effector cells, are …
Chimeric Antigen Receptor T-Cell Therapies In Lymphoma Patients With Central Nervous System Involvement, Dongni Yi, Mia Gergis, Ghada Elgohary, Jingmei Hsu, Yang Yang, Xia Bi, Usama Gergis
Chimeric Antigen Receptor T-Cell Therapies In Lymphoma Patients With Central Nervous System Involvement, Dongni Yi, Mia Gergis, Ghada Elgohary, Jingmei Hsu, Yang Yang, Xia Bi, Usama Gergis
Hematology/Oncology and Stem Cell Therapy
Background and objective: CAR T-cell therapy has significantly improved the outcomes of patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). However, most clinical trials excluded patients with central nervous system (CNS) involvement due to uncertain efficacy and safety. Material and methods: On January 1, 2022, we searched PubMed to identify all published literature associated with current commercial CAR T-cell therapies for B-NHL, including tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axicel), brexucabtagene autoleucel (brexu-cel), and lisocabtagene maraleucel (liso-cel). Studies that involved patients with either primary or secondary CNS lymphoma, and evaluated response rate, adverse events (AEs), or survival were included and …
Car-T Cell Therapies For B-Cell Lymphoid Malignancies: Identifying Targets Beyond Cd19, Yenny M. Vanegas, Razan Mohty, Martha E. Gadd, Yan Luo, Mahmoud Aljurf, Hong Qin, Mohamed A. Kharfan-Dabaja
Car-T Cell Therapies For B-Cell Lymphoid Malignancies: Identifying Targets Beyond Cd19, Yenny M. Vanegas, Razan Mohty, Martha E. Gadd, Yan Luo, Mahmoud Aljurf, Hong Qin, Mohamed A. Kharfan-Dabaja
Hematology/Oncology and Stem Cell Therapy
Chimeric antigen receptors (CARs) are synthetic engineered receptors with an antigen recognition domain derived from a high-specificity monoclonal antibody that can target surface molecules on tumor cells. T cells are genetically engineered to express CARs, thereby harnessing the antigen-recognition ability of antibodies and effector function of T cells. Target surface molecule selection is crucial for manufacturing CARs. Ideally, a target surface molecule should be restricted to tumor cells and minimally expressed or absent on normal tissues. Different CD19-targeted CAR-T cell therapies have been approved for the treatment of B-cell lymphoid malignancies that are refractory to other therapies, including indolent and …
Venetoclax Based Treatments As Frontline Therapy For Chronic Lymphocytic Leukemia, Guru Subramanian Guru Murthy, Ehab Atallah
Venetoclax Based Treatments As Frontline Therapy For Chronic Lymphocytic Leukemia, Guru Subramanian Guru Murthy, Ehab Atallah
Hematology/Oncology and Stem Cell Therapy
The availability of novel targeted agents has revolutionized the management of chronic lymphocytic leukemia (CLL). Both B-cell lymphoma 2 (BCL2) and Bruton tyrosine kinase (BTK) inhibitors are highly effective agents for CLL treatment. Several clinical trials have demonstrated the efficacy and safety of these agents in the management of newly diagnosed and relapsed/refractory CLL. This has led to two broad approaches in the frontline management of CLL, namely venetoclax-based time-limited therapy versus BTK inhibitor-based continuous therapy. In this review, we discussed why we consider venetoclax-based therapy as a suitable frontline option for patients with CLL.
Platelet Inventory And Using Out-Of-Group Platelet Suspension: A Cost-Effective Strategy For A Blood Transfusion Service, Abdulkerim Yıldız, Murat Dogan, Mehmet Yalvaç, Bilge Zihar
Platelet Inventory And Using Out-Of-Group Platelet Suspension: A Cost-Effective Strategy For A Blood Transfusion Service, Abdulkerim Yıldız, Murat Dogan, Mehmet Yalvaç, Bilge Zihar
Hematology/Oncology and Stem Cell Therapy
Background: Platelet (PLT) transfusions are essential for advanced hospitals, especially those with onco-hematology departments. However, platelet concentrates (PCs) have supply limitations and a shorter shelf life, which create difficulties for blood transfusion services (TSs). Materials and methods: This retrospective study was conducted over a 4-year period between January 2017 and January 2021 in a tertiary referral hospital. From the beginning of 2020, as a new strategy of our TSs, a PLT inventory was produced and ABO-identical transfusions were prioritized when the inventory allowed; when this was not possible, ABO and Rh incompatible transfusion was employed. The numbers of transfused and …